Expertise in
3
conditions

Dr. Inna Yuryev

Psychiatry
Office
2409 Ocean Ave Fl 1, 
Brooklyn, NY 
Offers Telehealth
Expertise in
3
conditions
Office
2409 Ocean Ave Fl 1, 
Brooklyn, NY 

Overview

Inna Yuryev is a Psychiatrist practicing medicine in Brooklyn, New York.

Dr. Yuryev is highly rated in 3 conditions, according to our data. Her clinical expertise encompasses Generalized Anxiety Disorder (GAD), Major Depression, Dementia, and Obsessive-Compulsive Disorder (OCD).

She is actively involved in clinical research, participating in 11 clinical trials.

Specialties

Psychiatry

Licenses

Psychiatry & Neurology in NY

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CenterLight Healthcare
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetroPlus Health
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Office
2409 Ocean Ave Fl 1, Brooklyn, NY 11229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2025
Intervention Type: Drug
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Long-Term Nicotine Treatment of Mild Cognitive Impairment
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Nicotine Transdermal Patch
Study Phase: Phase 2
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
A Phase 2a, Randomized, Double-blind, Placebo-controlled Proof of Concept Study to Evaluate the Effects of Oral BTRX-335140 (NMRA-335140) Versus Placebo in Subjects With Major Depressive Disorder
Enrollment Status: Completed
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drug: BTRX-335140
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
A Randomized , Double Blind, Placebo Controlled, 3-Arm Parallel Design Study to Evaluate the Effects of BPN14770 in Patients With Early Stage Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drug: BPN14770
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
1
conditions
Dr. Lenard Adler
Psychiatry
Expertise in
1
conditions
Dr. Lenard Adler
Psychiatry

NYU Langone Psychiatry Associates

1 Park Ave Fl 8, 
New York, NY 
 (9.9 miles away)
212-263-3580
Languages Spoken:
English
See accepted insurances

Lenard Adler is a Psychiatrist practicing medicine in New York, New York. Dr. Adler is highly rated in 1 condition, according to our data. His clinical expertise encompasses Attention Deficit Hyperactivity Disorder (ADHD).

Expertise in
1
conditions
Dr. John Rotrosen
Psychiatry
Expertise in
1
conditions
Dr. John Rotrosen
Psychiatry

Veterans Affairs New York Harbor Healthcare System-Manhattan Campus

423 E 23rd St, 
New York, NY 
 (9.4 miles away)
212-951-3294
Languages Spoken:
English

John Rotrosen is a Psychiatrist practicing medicine in New York, New York. Dr. Rotrosen is highly rated in 1 condition, according to our data. His clinical expertise encompasses Opioid Use Disorder.

Expertise in
2
conditions
Dr. Maria Oquendo
Psychiatry
Expertise in
2
conditions
Dr. Maria Oquendo
Psychiatry

Office

300 W 72nd St Apt 1F, 
New York, NY 
 (12.1 miles away)
212-721-2805
Languages Spoken:
English

Maria Oquendo is a Psychiatrist practicing medicine in New York, New York. Dr. Oquendo is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Major Depression, Bipolar Disorder (BPD), and Post-Traumatic Stress Disorder (PTSD).

Frequently Asked Questions about Dr. Inna Yuryev

How do I make an appointment with Dr. Inna Yuryev?

You can book an appointment with Dr. Inna Yuryev by calling their office at 718-444-7774. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Inna Yuryev a top-rated expert for Generalized Anxiety Disorder (GAD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Inna Yuryev is classified as an Distinguished expert for Generalized Anxiety Disorder (GAD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Inna Yuryev specialize in?

While Dr. Inna Yuryev is a Psychiatry, they have specific expertise in Generalized Anxiety Disorder (GAD), Major Depression, and Dementia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Psychiatry.

Does Dr. Inna Yuryev accept my insurance?

Dr. Inna Yuryev accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 718-444-7774 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Yuryev's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile